Stocks
Anika Therapeutics Financial Statements (ANIK) |
||||||||||
| Anika Therapeuticssmart-lab.ru | % | 2021 | 2022 | 2023 | 2023 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 11.03.2022 | 16.03.2023 | 31.12.2023 | 15.03.2024 | 26.04.2024 | 04.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 147.8 | 156.2 | 166.7 | 166.7 | 166.7 | 160.0 | |||
| Operating Income, bln rub | -18.5 | -19.4 | -25.4 | -87.6 | -25.4 | -57.8 | ||||
| EBITDA, bln rub | ? | 2.62 | -4.91 | -18.4 | 2.52 | -11.2 | -50.6 | |||
| Net profit, bln rub | ? | 4.13 | -14.9 | -82.7 | -82.7 | -82.7 | -64.4 | |||
| OCF, bln rub | ? | 8.40 | 4.41 | -1.79 | -1.79 | 3.82 | ||||
| CAPEX, bln rub | ? | 5.14 | 7.49 | 5.43 | 5.43 | 6.43 | ||||
| FCF, bln rub | ? | 3.25 | -3.08 | -7.22 | -7.22 | -2.61 | ||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 101.4 | 113.0 | 128.5 | 191.5 | 128.5 | 112.7 | ||||
| Cost of production, bln rub | 64.9 | 62.7 | 63.6 | 63.6 | 63.6 | 105.1 | ||||
| R&D, bln rub | 27.3 | 28.2 | 32.7 | 32.7 | 32.7 | 30.1 | ||||
| Interest expenses, bln rub | 0.000 | 0.654 | 0.000 | 0.000 | 2.31 | 0.592 | ||||
| Assets, bln rub | 347.5 | 349.1 | 270.6 | 270.6 | 270.6 | 231.4 | ||||
| Net Assets, bln rub | ? | 287.1 | 285.6 | 212.3 | 212.3 | 212.3 | 179.9 | |||
| Debt, bln rub | 19.2 | 30.9 | 26.9 | 29.0 | 29.0 | 27.5 | ||||
| Cash, bln rub | 94.4 | 86.3 | 72.9 | 72.9 | 72.9 | 62.4 | ||||
| Net debt, bln rub | -75.1 | -55.4 | -46.0 | -43.8 | -43.8 | -34.8 | ||||
| Ordinary share price, rub | 35.8 | 29.6 | 22.7 | 22.7 | 22.7 | 20.0 | ||||
| Number of ordinary shares, mln | 14.4 | 14.6 | 14.7 | 14.7 | 14.7 | 14.8 | ||||
| Market cap, bln rub | 516 | 431 | 332 | 332 | 332 | 295 | ||||
| EV, bln rub | ? | 441 | 376 | 286 | 288 | 288 | 261 | |||
| Book value, bln rub | 197 | 204 | 205 | 200 | 200 | 169 | ||||
| EPS, rub | ? | 0.29 | -1.02 | -5.64 | -5.64 | -5.64 | -4.36 | |||
| FCF/share, rub | 0.23 | -0.21 | 0.00 | -0.49 | -0.49 | -0.18 | ||||
| BV/share, rub | 13.7 | 14.0 | 14.0 | 13.7 | 13.7 | 11.5 | ||||
| EBITDA margin, % | ? | 1.77% | -3.14% | -11.0% | 1.51% | -6.73% | -31.7% | |||
| Net margin, % | ? | 2.80% | -9.51% | -49.6% | -49.6% | -49.6% | -40.3% | |||
| FCF yield, % | ? | 0.63% | -0.71% | 0.00% | -2.17% | -2.17% | -0.88% | |||
| ROE, % | ? | 1.44% | -5.20% | -38.9% | -38.9% | -38.9% | -35.8% | |||
| ROA, % | ? | 1.19% | -4.26% | -30.5% | -30.5% | -30.5% | -27.8% | |||
| P/E | ? | 124.8 | -29.0 | -4.02 | -4.02 | -4.02 | -4.58 | |||
| P/FCF | 158.6 | -140.1 | -46.0 | -46.0 | -113.3 | |||||
| P/S | ? | 3.49 | 2.76 | 1.99 | 1.99 | 1.99 | 1.85 | |||
| P/BV | ? | 2.62 | 2.12 | 1.62 | 1.66 | 1.66 | 1.75 | |||
| EV/EBITDA | ? | 168.6 | -76.4 | -15.6 | 114.6 | -25.7 | -5.14 | |||
| Debt/EBITDA | -28.7 | 11.3 | 2.50 | -17.4 | 3.91 | 0.69 | ||||
| R&D/CAPEX, % | 531.3% | 376.5% | 602.4% | 602.4% | 467.6% | |||||
| CAPEX/Revenue, % | 3.48% | 4.79% | 0.00% | 3.26% | 3.26% | 4.02% | ||||
| Anika Therapeutics shareholders | ||||||||||
